Evidence map›Paper›PMID 36183949›Full record

ArticleJournal of ethnopharmacology2023

Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway.

Yanhui Zhu, Qianqian Han, Lei Wang, Baiyan Wang, Jianshuang Chen, Bangrong Cai, Can Wu, Xiali Zhu, Fugang Liu, Deen Han and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of ethnopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Journal of microbiology and biotechnology · 2025
    Article
  18. Article
  19. Article
  20. Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yanhui ZhuSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: judy202426@126.com.
Qianqian HanSchool of Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: hanqianll@hactcm.edu.cn.
Lei WangSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: 838133668@qq.com.
Baiyan WangSchool of Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: baiyanw@hactcm.edu.cn.
Jianshuang ChenSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: 511447685@qq.com.
Bangrong CaiSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: cbr2018@hactcm.edu.cn.
Can WuSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: wucan_bz@hactcm.edu.cn.
Xiali ZhuSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: zhuxiali1980@126.com.
Fugang LiuSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: 13526585635@163.com.
Deen HanSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: handn@163.com.
Haoran DongAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: haoranxc@163.com.
Yongyan JiaSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: hnzyjyy@126.com.
Yalin LiuSchool of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, 450046, China. Electronic address: liuyalin_1984@163.com.
First Affiliated Hospital of Henan University · CNHenan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ethnopharmacological relevanceAcute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration in the treatment of H1N1 influenza and mild or moderate novel coronavirus disease 2019 (COVID-19), which is an herbal formula developed based on Maxingshigan decoction and Yinqiao powder that have been used to respiratory diseases in China for thousands of years. However, the underlying mechanism of JHQG in treating infectious diseases remains unclear. AIM OF THE STUDY: This study investigated the effects of JHQG on neutrophil apoptosis and key signaling pathways in lipopolysaccharide (LPS) -induced ALI mice in order to explore its mechanism of anti-inflammation. MATERIALS AND

methodsThe effect of JHQG on survival rate was observed in septic mouse model by intraperitoneal injection of LPS (20 mg/kg). To better pharmacological evaluation, the mice received an intratracheal injection of 5 mg/kg LPS. Lung histopathological changes, wet-to-dry ratio of the lungs, and MPO activity in the lungs and total protein concentration, total cells number, TNF-α, IL-1β, IL-6, and MIP-2 levels in BALF were assessed. Neutrophil apoptosis rate was detected by Ly6G-APC/Annexin V-FITC staining. Key proteins associated with apoptosis including caspase 3/7 activity, Bcl-xL and Mcl-1 were measured by flow cytometry and confocal microscope, respectively. TLR4 receptor and its downstream signaling were analyzed by Western blot assay and immunofluorescence, respectively.

resultsJHQG treatment at either 6 or 12 g/kg/day resulted in 20% increase of survival in 20 mg/kg LPS-induced mice. In the model of 5 mg/kg LPS-induced mice, JHQG obviously decreased the total protein concentration in BALF, wet-to-dry ratio of the lungs, and lung histological damage. It also attenuated the MPO activity and the proportion of Ly6G staining positive neutrophils in the lungs, as well as the MIP-2 levels in BALF were reduced. JHQG inhibited the expression of Mcl-1 and Bcl-xL and enhanced caspase-3/7 activity, indicating that JHQG partially acted in promoting neutrophil apoptosis via intrinsic mitochondrial apoptotic pathway. The levels of TNF-α, IL-1β, and IL-6 were significantly declined in LPS-induced mice treated with JHQG. Furthermore, JHQG reduced the protein expression of TLR4, MyD88, p-p65 and the proportion of nuclei p65, suggesting that JHQG treatment inhibited TLR4/MyD88/NF-κB pathway.

conclusionJHQG reduced pulmonary inflammation and protected mice from LPS-induced ALI by promoting neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway, suggesting that JHQG may be a promising drug for treatment of ALI.

Indexed as

Acute Lung InjuryCOVID-19Influenza A Virus, H1N1 SubtypeAnimalsApoptosisDrugs, Chinese HerbalInterleukin-6LipopolysaccharidesMiceMyeloid Cell Leukemia Sequence 1 ProteinMyeloid Differentiation Factor 88NeutrophilsNF-kappa BToll-Like Receptor 4Tumor Necrosis Factor-alphaDrugs, Chinese HerbalInterleukin-6jinhua qinggan granulesLipopolysaccharidesMyd88 protein, mouseMyeloid Cell Leukemia Sequence 1 ProteinMyeloid Differentiation Factor 88NF-kappa BTlr4 protein, mouseToll-Like Receptor 4Tumor Necrosis Factor-alphaAcute lung injuryJinhua Qinggan granulesNeutrophil apoptosisNuclear factor kappa-BToll-like receptor 4

Identifiers

PMID36183949
PMCPMC9523948
OpenAlexW4298009196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.